- Home
- DBVT vs IMMP Comparison
DBVT vs IMMP Comparison
Compare DBVT & IMMP Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- DBVT
- IMMP
- Stock Information
- Founded
- DBVT 2002
- IMMP 1987
- Country
- DBVT France
- IMMP Australia
- Employees
- DBVT N/A
- IMMP N/A
- Industry
- DBVT Biotechnology: Biological Products (No Diagnostic Substances)
- IMMP Biotechnology: Pharmaceutical Preparations
- Sector
- DBVT Health Care
- IMMP Health Care
- Exchange
- DBVT Nasdaq
- IMMP Nasdaq
- Market Cap
- DBVT 237.4M
- IMMP 251.8M
- IPO Year
- DBVT N/A
- IMMP N/A
- Fundamental
- Price
- DBVT $9.40
- IMMP $1.60
- Analyst Decision
- DBVT Buy
- IMMP Buy
- Analyst Count
- DBVT 4
- IMMP 1
- Target Price
- DBVT $14.81
- IMMP $7.00
- AVG Volume (30 Days)
- DBVT 41.9K
- IMMP 97.6K
- Earning Date
- DBVT 07-29-2025
- IMMP 02-27-2025
- Dividend Yield
- DBVT N/A
- IMMP N/A
- EPS Growth
- DBVT N/A
- IMMP N/A
- EPS
- DBVT N/A
- IMMP N/A
- Revenue
- DBVT $3,497,000.00
- IMMP $3,019,249.00
- Revenue This Year
- DBVT $1,700.53
- IMMP $50.37
- Revenue Next Year
- DBVT $535.67
- IMMP N/A
- P/E Ratio
- DBVT N/A
- IMMP N/A
- Revenue Growth
- DBVT N/A
- IMMP 24.11
- 52 Week Low
- DBVT $2.21
- IMMP $1.32
- 52 Week High
- DBVT $12.78
- IMMP $2.80
- Technical
- Relative Strength Index (RSI)
- DBVT 52.73
- IMMP 34.41
- Support Level
- DBVT $9.00
- IMMP $1.81
- Resistance Level
- DBVT $10.12
- IMMP $1.92
- Average True Range (ATR)
- DBVT 0.57
- IMMP 0.08
- MACD
- DBVT 0.08
- IMMP -0.03
- Stochastic Oscillator
- DBVT 72.24
- IMMP 0.00
About DBVT DBV Technologies S.A.
DBV Technologies SA is a clinical-stage specialty biopharmaceutical company focused on changing the field of immunotherapy by developing a novel technology platform called Viaskin. The therapeutic approach is based on epicutaneous immunotherapy or EPIT, its proprietary method of delivering biologically active compounds to the immune system through intact skin using Viaskin, an epicutaneous patch (i.e., a skin patch). Its main product candidate under development is Viaskin Peanut for the treatment of peanut-allergic patients. In addition, the company also has earlier-stage food allergy programs, including Viaskin Milk and Eosinophilic Esophagitis, or EoE.
About IMMP Immutep Limited
Immutep Ltd is a globally active biotechnology company developing immunotherapy products for cancer and autoimmune diseases. Its main product is IMP321, which involves clinical development for the treatment of cancer indications. The company is also focused on the development of other products, which include IMP701, which is a blocking anti-LAG-3 antibody for cancer and is in Phase I of its clinical trials, and CVac, which is a personalized immunocellular therapeutic investigated for the treatment of epithelial cancer. Geographically all the business activity of the firm is functioned through the region of Australia.